Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma
This is a single arm, prospective trial to evaluate the efficacy and safety of Chidamide in combination with previous chemotherapy in peripheral T cell lymphoma patients who did not achieve complete response after 3 cycles of chemotherapy in interim evaluation.
Peripheral T Cell Lymphoma
DRUG: Chidamide
complete response, 21 days after 3 cycles of chidamide in combination with chemotherapy (each cycle is 21 days)
Progression free survival, 1 year|Overall survival, 1 year|Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0, Each cycle of treatment and then every 3 months for 1 year（each cycle is 21 days）
This is a single arm, prospective trial to evaluate the efficacy and safety of Chidamide in combination with previous chemotherapy in peripheral T cell lymphoma patients who did not achieve complete response after 3 cycles of chemotherapy in interim evaluation.